# Testing the Combination of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) in Children, Adolescent, and Young Adult Patients With Relapsed/Refractory Cancers That Have an Increased Number of Genetic Changes, The 3CI Study

> **NCT04500548** · PHASE1 · WITHDRAWN · sponsor: **National Cancer Institute (NCI)**

## Conditions studied

- Constitutional Mismatch Repair Deficiency Syndrome
- Hematopoietic and Lymphoid Cell Neoplasm
- Lynch Syndrome
- Recurrent Lymphoma
- Recurrent Malignant Solid Neoplasm
- Recurrent Neuroblastoma
- Recurrent Primary Central Nervous System Neoplasm
- Refractory Lymphoma
- Refractory Malignant Solid Neoplasm
- Refractory Neuroblastoma
- Refractory Primary Central Nervous System Neoplasm
- Xeroderma Pigmentosum

## Interventions

- **PROCEDURE:** Biospecimen Collection
- **BIOLOGICAL:** Ipilimumab
- **BIOLOGICAL:** Nivolumab

## Key facts

- **NCT ID:** NCT04500548
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2021-01-28
- **Primary completion:** 2022-06-21
- **Final completion:** 2022-06-21
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Inadequate accrual rate
- **Last updated:** 2025-09-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04500548

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04500548, "Testing the Combination of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) in Children, Adolescent, and Young Adult Patients With Relapsed/Refractory Cancers That Have an Increased Number of Genetic Changes, The 3CI Study". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT04500548. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*